^
Association details:
Biomarker:BCL2 overexpression
Cancer:Diffuse Large B Cell Lymphoma
Regimen: (cyclophosphamide + doxorubicin hydrochloride + prednisone + Rituxan (rituximab) + vincristine)
Direction:Resistant
Evidence:
Evidence Level:
Resistant: C3 – Early Trials
Source:
Title:

BCL2 super-expressor diffuse large B-cell lymphoma: a distinct subgroup associated with poor prognosis

Published date:
11/11/2021
Excerpt:
We aimed to evaluate the prognostic value of BCL2 expression determined by immunohistochemistry (IHC), incorporating both the staining intensity and proportion, in patients with de novo DLBCL who received rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) as first-line treatment....The BCL2 super-expressors (n = 35) showed significantly worse event-free survival (EFS; HR, 1.903; 95% CI, 1.159-3.126, P = 0.011) and overall survival (OS; HR, 2.467; 95% CI, 1.474-4.127, P = 0.001)...
DOI:
10.1038/s41379-021-00962-z